IVA: Clinical Trials

9 trials of IVA, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

8 completed, 1 terminated. 9 Phase 2, 3 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 29Completed 8, Terminated 1
Phase 13Completed 3

Follow IVA: new trials by email Literature Review of IVA trials Research Report on IVA

Trials (filtered) newest first · largest first

All 9 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Phase 1/2 Study of VX-522 in Participants With Cystic Fibrosis (CF)
VX-522 mRNA therapy, IVA - Cystic Fibrosis
Phase 1 / Phase 2CompletedVertex Pharmaceuticals Incorporated262023-02-272026-10-09
A Study to Evaluate the Safety and Efficacy of VX-121 Combination Therapy in Subjects With Cystic Fibrosis
VX-121, TEZ, VX-561 - Cystic Fibrosis
Phase 2CompletedVertex Pharmaceuticals Incorporated872019-04-302023-04-20
A Phase 2 Study to Evaluate Efficacy and Safety of VX-561 in Subjects Aged 18 Years and Older With Cystic Fibrosis
VX-561, IVA, Placebo - Cystic Fibrosis
Phase 2CompletedVertex Pharmaceuticals Incorporated772019-04-172022-01-25
Study of VX-121 in Healthy Subjects and in Subjects With Cystic Fibrosis
Placebo (matched to VX-121 suspension), VX-121 (Suspension), TEZ/IVA - Cystic Fibrosis
Phase 1 / Phase 2CompletedVertex Pharmaceuticals Incorporated1152018-03-202022-07-14
A Study Evaluating the Safety and Efficacy of VX-659 Combination Therapy in Subjects With Cystic Fibrosis
VX-659, TEZ/IVA, IVA - Cystic Fibrosis
Phase 2CompletedVertex Pharmaceuticals Incorporated1242017-08-082021-04-22
A Study of VX-445 in Healthy Subjects and Subjects With Cystic Fibrosis
IVA, TEZ/IVA, VX-445 - Cystic Fibrosis
Phase 1 / Phase 2CompletedVertex Pharmaceuticals Incorporated2252017-01-232022-01-18
Study to Evaluate the Safety and Efficacy of CTP-656 in Patients With Cystic Fibrosis With CFTR Gating Mutations
VX-561, Placebo, IVA - Cystic Fibrosis
Phase 2TerminatedVertex Pharmaceuticals Incorporated112016-12-012020-08-26
A Study Evaluating the Safety of VX-152 Combination Therapy in Adults With Cystic Fibrosis
VX-152, TEZ/IVA, IVA - Cystic Fibrosis
Phase 2CompletedVertex Pharmaceuticals Incorporated802016-11-012021-01-28
A Study Evaluating the Safety and Efficacy of VX-440 Combination Therapy in Subjects With Cystic Fibrosis
TEZ, IVA, VX-440 - Cystic Fibrosis
Phase 2CompletedVertex Pharmaceuticals Incorporated742016-10-012020-08-28

Conditions studied

Cystic Fibrosis (9)

Sponsors

Vertex Pharmaceuticals Incorporated (9)

Countries

United States (8)  ·  United Kingdom (6)  ·  Australia (4)  ·  Belgium (4)  ·  Germany (4)  ·  Netherlands (4)  ·  Canada (2)  ·  Ireland (2)  ·  Austria (1)  ·  Denmark (1)  ·  Israel (1)  ·  Italy (1)  ·  Portugal (1)  ·  Spain (1)  ·  Sweden (1)

Results publications

PMID 33331662, PMID 36842446, PMID 37983082, PMID 30334692, PMID 30334693

NIH funding

2016 (2), 2018 (2), 2017 (1), 2023 (1)